Glenmark gets USFDA nod for generic blood pressure medicine
Shares of Glenmark Pharmaceuticals were trading 2.17 percent up at Rs 625.20 on BSE
New Delhi, May 26 (PTI) Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil Tablets, used in treatment of high blood pressure.
The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg, the company said in a statement.
These are generic equivalent of Benicar Tablets of Daiichi Sankyo, Inc. Glenmark's Olmesartan Medoxomil tablets will be manufactured by the company's manufacturing facility located in Goa, India, it added.
Citing IMS Health sales data for the 12-month period ended March 2017, the company said Benicar achieved annual sales of about USD 950 million.
Glenmark's current portfolio consists of 115 products authorised for distribution in the US market and approximately 69 ANDA's (Abbreviated New Drug Application) pending approval with the USFDA.
Shares of Glenmark Pharmaceuticals were trading 2.17 percent up at Rs 625.20 on BSE.
Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.
A 2010 study suggests that cardiovascular complications are the major cause of death among 70 percent of patients with Type 2 diabetes
Adding oil of acebuche, type of Spanish wild olive tree, to your diet can reduce arterial hypertension, suggests study
Hypertension or high blood pressure is a chronic disease that leads to an increased risk of heart disease, stroke and other health issues